We work with clients who believe research strengthens decision-making.
Our client list is local and global, including emerging challengers and market leaders.
Our business is heavily concentrated in financial services, healthcare and technology ... yet we have conducted B2C and B2B research in almost any other subject area you can imagine.
This is where we sit, we own our own tools, we control quality and speed.
Limited capacity, do not own tools, cannot control quality and timeliness due to dependency upon external resources.
Not interested in business valued at less than 7 figures, slow-moving, inflexible.
A fighter brand telecommunications provider had more quantitative data than you could shake a stick at. Yet, it was having trouble figuring out how to up the ante on its next communications campaign designed to attract value-driven new subscribers. What did our research discover? Their mascot was a keeper. No one liked their 30 second TV spots, better to go with 15 seconds for young clients suffering from attention deficit disorder. Messages needed to focus on price and deals, not just the brand's personality. Can't get much simpler than that.
A large wealth management company wanted to generate earned media in space in which everything has already been said. A casual conversation with a friend about being divorced at age 50 led us down the path of a study about financial disrupters that shattered all previous earned media records for the Company. Quantifying the carnage at $2.5 trillion in lost long-term and retirement savings drove strong media interest.
The manufacturer of the most widely used biologic in North America was cognizant of the potential financial burden of biologics on third party payers. We established a steering committee comprised of key employers, health benefits consultants and third party payers, then undertook primary research to understand current perceptions of biologics, as well as experiences with management and reimbursement strategies to contain costs. Insights were used to create a Bio-Insight white paper that shed light on how biologics are perceived by stakeholders and plan sponsors, how biologics are currently being covered and examining future cost containment strategies.